The approval was based on results from the Phase II HORIZON-Lung trial, in which the treatment had a median progression-free survival of 11.5 months.

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

Merck (MRK) stock falls as the company withdraws U.S. marketing application for lung cancer therapy HER3-DXd developed with ...

Pembrolizumab plus CRT produced “robust and durable anti-tumor activity” in the KEYNOTE-799 trial, said Martin Reck, MD, PhD.

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven ...

Breathing in wildfire pollution may make it harder for people with lung cancer to survive, according to a new study from UC ...